Antipsychotische Pharmakotherapie bei deliranten Syndromen: Nur zeitlich begrenzt, symptomorientiert und unter Beachtung der QTc-Zeit

Translated title of the contribution: Antipsychotic pharmacotherapy for delirious syndromes — only temporary, symptom-oriented and considering QTc time

Dirk Schwerthöffer, Hans Förstl, Bastian Fatke

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Background: QTc prolongation is a common and serious side effect of antipsychotics in the treatment of delirium. Nevertheless, the occurrence of ventricular tachycardia is rarely reported, so that the clinical relevance of a QTc prolongation triggered in this way remains unclear. Method: The focus of this review is on the antipsychotic pharmacotherapy of delirium. Results and Conclusions: In individual cases, before the prescription of an antipsychotic due to a delirium, a risk-benefit assessment must be made for the patient. For this purpose, patient and substance-specific risk factors for QTc prolongation must be checked and, if possible, reduced. A specific recommendation for an antipsychotic with assured low QTc interference can not be given because all antipsychotics for delirium treatment are potentially QTc-prolonging. Antipsychotic delirium treatment should be monitored, especially in patients with a high risk profile, for QTc prolongation by regular ECG controls.

Translated title of the contributionAntipsychotic pharmacotherapy for delirious syndromes — only temporary, symptom-oriented and considering QTc time
Original languageGerman
Pages (from-to)1-6
Number of pages6
JournalMMW-Fortschritte der Medizin
Volume161
DOIs
StatePublished - 1 Jul 2019
Externally publishedYes

Fingerprint

Dive into the research topics of 'Antipsychotic pharmacotherapy for delirious syndromes — only temporary, symptom-oriented and considering QTc time: Nur zeitlich begrenzt, symptomorientiert und unter Beachtung der QTc-Zeit'. Together they form a unique fingerprint.

Cite this